Enhanced prediction of postoperative radiotherapy-induced esophagitis in non-small cell lung cancer: Dosiomic model development in a real-world cohort and validation in the PORT-C randomized controlled trial
- PMID: 37596813
- PMCID: PMC10542460
- DOI: 10.1111/1759-7714.15068
Enhanced prediction of postoperative radiotherapy-induced esophagitis in non-small cell lung cancer: Dosiomic model development in a real-world cohort and validation in the PORT-C randomized controlled trial
Abstract
Background: Radiotherapy-induced esophagitis (RE) diminishes the quality of life and interrupts treatment in patients with non-small cell lung cancer (NSCLC) undergoing postoperative radiotherapy. Dosimetric models showed limited capability in predicting RE. We aimed to develop dosiomic models to predict RE.
Methods: Models were trained with a real-world cohort and validated with PORT-C randomized controlled trial cohort. Patients with NSCLC undergoing resection followed by postoperative radiotherapy between 2004 and 2015 were enrolled. The endpoint was grade ≥2 RE. Esophageal three-dimensional dose distribution features were extracted using handcrafted and convolutional neural network (CNN) methods, screened using an entropy-based method, and selected using minimum redundancy and maximum relevance. Prediction models were built using logistic regression. The areas under the receiver operating characteristic curve (AUC) and precision-recall curve were used to evaluate prediction model performance. A dosimetric model was built for comparison.
Results: A total of 190 and 103 patients were enrolled in the training and validation sets, respectively. Using handcrafted and CNN methods, 107 and 4096 features were derived, respectively. Three handcrafted, four CNN-extracted and three dosimetric features were selected. AUCs of training and validation sets were 0.737 and 0.655 for the dosimetric features, 0.730 and 0.724 for handcrafted features, and 0.812 and 0.785 for CNN-extracted features, respectively. Precision-recall curves revealed that CNN-extracted features outperformed dosimetric and handcrafted features.
Conclusions: Prediction models may identify patients at high risk of developing RE. Dosiomic models outperformed the dosimetric-feature model in predicting RE. CNN-extracted features were more predictive but less interpretable than handcrafted features.
Keywords: convolution neural network; dosiomics; non-small cell lung cancer; prediction model; radiation esophagitis.
© 2023 The Authors. Thoracic Cancer published by China Lung Oncology Group and John Wiley & Sons Australia, Ltd.
Conflict of interest statement
The authors declare that they have no competing interests.
Figures



Similar articles
-
Multi-institutional dose-segmented dosiomic analysis for predicting radiation pneumonitis after lung stereotactic body radiation therapy.Med Phys. 2021 Apr;48(4):1781-1791. doi: 10.1002/mp.14769. Epub 2021 Mar 2. Med Phys. 2021. PMID: 33576510
-
Combined deep learning and radiomics in pretreatment radiation esophagitis prediction for patients with esophageal cancer underwent volumetric modulated arc therapy.Radiother Oncol. 2024 Oct;199:110438. doi: 10.1016/j.radonc.2024.110438. Epub 2024 Jul 14. Radiother Oncol. 2024. PMID: 39013503
-
Dosiomics and radiomics improve the prediction of post-radiotherapy neutrophil-lymphocyte ratio in locally advanced non-small cell lung cancer.Med Phys. 2024 Jan;51(1):650-661. doi: 10.1002/mp.16829. Epub 2023 Nov 14. Med Phys. 2024. PMID: 37963229
-
Esophagitis, treatment-related toxicity in non-small cell lung cancer.Rev Recent Clin Trials. 2012 Feb;7(1):31-5. doi: 10.2174/157488712799363235. Rev Recent Clin Trials. 2012. PMID: 21864251 Free PMC article. Review.
-
A systematic review and meta-analysis of the utility of quantitative, imaging-based approaches to predict radiation-induced toxicity in lung cancer patients.Radiother Oncol. 2025 Jul;208:110935. doi: 10.1016/j.radonc.2025.110935. Epub 2025 May 11. Radiother Oncol. 2025. PMID: 40360049 Review.
Cited by
-
Postoperative radiotherapy enhances survival in NSCLC patients with moderate lymph node metastases following surgery: A SEER-based population cohort study.Medicine (Baltimore). 2025 Jul 25;104(30):e43367. doi: 10.1097/MD.0000000000043367. Medicine (Baltimore). 2025. PMID: 40725918 Free PMC article.
-
Higher immune cell radiation dose is correlated with poor tumor control and survival in patients with non-small cell lung cancer receiving postoperative radiotherapy.BMC Cancer. 2024 Aug 8;24(1):968. doi: 10.1186/s12885-024-12699-4. BMC Cancer. 2024. PMID: 39112971 Free PMC article.
-
Preoperative CT-based radiomic prognostic index to predict the benefit of postoperative radiotherapy in patients with non-small cell lung cancer: a multicenter study.Cancer Imaging. 2024 May 13;24(1):61. doi: 10.1186/s40644-024-00707-6. Cancer Imaging. 2024. PMID: 38741207 Free PMC article.
References
-
- Hui Z, Men Y, Hu C, Kang J, Sun X, Bi N, et al. Effect of postoperative radiotherapy for patients with pIIIA‐N2 non‐small cell lung cancer after complete resection and adjuvant chemotherapy: the phase 3 PORT‐C randomized clinical trial. JAMA Oncol. 2021;7:1178–1185. 10.1001/jamaoncol.2021.1910 - DOI - PMC - PubMed
-
- Le Pechoux C, Pourel N, Barlesi F, Lerouge D, Antoni D, Lamezec B, et al. Postoperative radiotherapy versus no postoperative radiotherapy in patients with completely resected non‐small‐cell lung cancer and proven mediastinal N2 involvement (lung ART): an open‐label, randomised, phase 3 trial. Lancet Oncol. 2022;23:104–114. 10.1016/S1470-2045(21)00606-9 - DOI - PubMed
-
- Machtay M, Hsu C, Komaki R, Sause WT, Swann RS, Langer CJ, et al. Effect of overall treatment time on outcomes after concurrent chemoradiation for locally advanced non‐small‐cell lung carcinoma: analysis of the radiation therapy oncology group (RTOG) experience. Int J Radiat Oncol Biol Phys. 2005;63:667–671. 10.1016/j.ijrobp.2005.03.037 - DOI - PubMed
-
- Kuroda Y, Sekine I, Sumi M, Sekii S, Takahashi K, Inaba K, et al. Acute radiation esophagitis caused by high‐dose involved field radiotherapy with concurrent cisplatin and vinorelbine for stage III non‐small cell lung cancer. Technol Cancer Res Treat. 2013;12:333–339. 10.7785/tcrt.2012.500319 - DOI - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical